查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086211

帕金森氏症治療市場：2026-2032年全球市場預測（按藥物類別、療法、給藥途徑、目標領域、分銷管道和最終用戶分類）

Parkinson's Disease Therapeutics Market by Drug Class, Therapy Type, Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，帕金森氏症治療市場將成長至 89.8 億美元，複合年成長率為 6.50%。

主要市場統計數據
基準年 2025 57.8億美元
預計年份：2026年 61.4億美元
預測年份 2032 89.8億美元
複合年成長率 (%) 6.50%

帕金森氏症藥物用於治療一種進行性神經退化性併發症，其特徵是運動症狀，如震顫、肌肉僵硬、運動遲緩和姿勢神經退化性疾病，如睡眠障礙、憂鬱症、進行性、便秘、疼痛、疲勞和認知障礙。

根據世界衛生組織（WHO）的數據，2019年全球帕金森氏症患者人數超過850萬，在過去25年中增加了一倍以上。這導致臨床上對左旋多巴類藥物、多巴胺促效劑、MAO-B抑制劑、COMT抑制劑、金剛烷胺、抗膽鹼能藥物、醫療設備療法、復健護理以及針對潛在神經退化的臨床實驗療法等治療方法產生了持續的需求。

治療前景的變革性變化

帕金森氏症的治療方法正從單純控制症狀轉向早期診斷、個人化治療方案製定和更永續的給藥系統。臨床醫生擴大將藥物治療與深部腦部刺激、輸液治療、復健治療、言語和物理治療以及數位監測相結合，以應對疾病帶來的波動性負擔並維持患者的日常生活功能。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在帕金森氏症的各個領域創造累積價值，從藥物發現和臨床開發到診斷和醫療服務。 AI 驅動的分析可以支持靶點識別、分子篩檢、患者分層、影像診斷、語音分析、步態評估、震顫特徵分析、藥物反應追蹤，甚至可以使用穿戴式裝置和智慧型手機進行遠端監測。

對關鍵區域的洞察

北美憑藉其先進的神經系統基礎設施、受美國食品藥物管理局 (FDA) 監管的創新途徑、高診斷率、活躍的臨床試驗活動以及廣泛的專業藥物和醫療設備，仍然是帕金森氏症治療領域的領先地區。歐洲則受益於完善的運動障礙網路、歐洲藥品管理局 (EMA) 的監管、國家醫療保險報銷體系、醫療技術評估以及在藥物治療、手術治療、數位療法和復健治療方面對帕金森氏症治療的積極研究。

關鍵的群體特定見解

歐盟和七國集團透過規範的臨床試驗、學術神經病學中心、藥物安全監測系統、醫療技術評估以及對已證實具有臨床價值的療法的保險報銷，為全球帕金森氏症治療創新生態系統提供了重要支持。北約成員國也透過建立穩健的醫療供應鏈、開展跨境研究合作、完善的醫療基礎設施以及許多先進醫療系統通用的標準化品質標準做出貢獻。

主要國家的概況

美國透過FDA批准、專科醫療網路、聯邦醫療保險覆蓋、運動障礙中心以及積極的臨床試驗，引領商業性化應用。而加拿大則強調公共保險報銷、基於指南的醫療保健以及各省之間公平的醫療服務取得。墨西哥和巴西對價格合理的學名藥、更廣泛的神經系統疾病治療以及更完善的治療連續性的需求日益成長，其中巴西的公共醫療體系在提供基本藥物和專科醫療服務方面發揮著核心作用。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠解決運動變異性、運動障礙、藥效減退、非運動症狀、用藥依從性、安全性以及看護者負擔等問題的療法。強大的差異化優勢需要真實世界數據、患者報告結果、客觀的數位化指標以及超越傳統評估量表的可衡量的功能性效益。

調查方法

本執行摘要基於對公開的臨床、監管、流行病學和衛生政策資訊來源的三角二次調查，包括世衛組織疾病負擔數據、國家法規結構、治療指南、同行檢驗文獻、臨床試驗註冊資訊、藥物警戒參考資料和保險報銷資訊。

結論

隨著人口老化導致帕金森氏症患者病率上升，患者的需求也從單純的症狀性運動功能管理擴展到非運動症狀、長期功能、獨立生活能力以及看護者支持等領域，帕金森氏症藥物仍將是醫療保健領域的重中之重。目前的標準治療方案仍然至關重要，但給藥方式、生物標記、數位化終點指標以及實證緩解疾病研究等方面的創新將日益影響帕金森氏症藥物治療的競爭格局。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：帕金森氏症治療市場：依藥物類別分類

  • 抗膽鹼能藥物
    • 苯扎托品
    • 三己安非他命
  • COMT抑制劑
    • entacapone
    • 托魯卡蓬
  • 多巴胺促效劑
  • 左多巴
  • MAO-B抑制劑

第8章：帕金森氏症治療市場：依治療類型分類

  • 製藥
  • 非藥物療法
    • 深部腦部刺激療法
    • 物理治療
    • 語言治療

第9章：帕金森氏症治療市場：依給藥途徑分類

  • 靜脈注射
  • 注射藥物
  • 口服
  • 經皮給藥

第10章：帕金森氏症治療市場：依目標區域分類

  • 非典型帕金森症候群
  • 藥物誘發的帕金森氏症候群
  • 遺傳性帕金森氏症
  • 特發性帕金森氏症
  • 血管型帕金森症候群

第11章：帕金森氏症治療市場：依通路分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第12章：帕金森氏症治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章：帕金森氏症治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：帕金森氏症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：帕金森氏症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Novartis AG
  • UCB SA
  • Amneal Pharmaceuticals LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Orion Corporation
  • Teva Pharmaceutical Industries Limited
  • H. Lundbeck A/S
  • Eisai Co., Ltd.
  • Amyl Therapeutics SRL
  • Apotex Inc.
  • Aspen Neuroscience, Inc.
  • Bayer AG
  • Biogen Inc.
  • BlueRock Therapeutics LP by Bayer AG
  • Brainstorm Cell Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • Cerevance, LLC
  • Cipla Limited
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Muna Therapeutics ApS
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market is projected to grow by USD 8.98 billion at a CAGR of 6.50% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.78 billion
Estimated Year [2026] USD 6.14 billion
Forecast Year [2032] USD 8.98 billion
CAGR (%) 6.50%

Parkinson's disease therapeutics address a progressive neurodegenerative disorder marked by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability, as well as non-motor complications including sleep disruption, depression, autonomic dysfunction, constipation, pain, fatigue, and cognitive impairment.

The World Health Organization reports that global Parkinson's disease prevalence exceeded 8.5 million people in 2019 and has more than doubled over the past 25 years. This creates sustained clinical demand for levodopa-based regimens, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, device-aided therapies, rehabilitative care, and investigational disease-modifying approaches targeting underlying neurodegeneration.

Transformative Shifts in the Therapeutics Landscape

The Parkinson's disease therapeutics landscape is shifting from symptom control alone toward earlier diagnosis, personalized treatment sequencing, and longer-lasting delivery systems. Clinicians increasingly combine pharmacologic therapy with deep brain stimulation, infusion-based approaches, rehabilitation, speech and physical therapy, and digital monitoring to manage fluctuating disease burden and preserve daily function.

Pipeline activity is also moving toward alpha-synuclein biology, neuroinflammation, mitochondrial dysfunction, lysosomal pathways, gene therapy, cell therapy, and biomarker-guided trials. However, payers and health systems continue to require evidence of meaningful improvement in daily function, safety, adherence, caregiver burden, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across Parkinson's disease drug discovery, clinical development, diagnosis, and care delivery. AI-enabled analytics can support target identification, molecule screening, patient stratification, imaging interpretation, speech analysis, gait assessment, tremor characterization, medication response tracking, and remote monitoring through wearable and smartphone-based data.

The strongest near-term impact is expected in trial enrichment and digital endpoints, where objective movement, sleep, speech, and activity data may reduce variability and improve sensitivity to treatment effects. Adoption still depends on clinical validation, explainable models, cybersecurity, representative datasets, physician workflow integration, and alignment with medical device and software regulatory requirements.

Key Regional Insights

North America remains a leading environment for Parkinson's disease therapeutics due to advanced neurology infrastructure, FDA-regulated innovation pathways, high diagnosis rates, clinical trial activity, and strong adoption of specialty drugs and device-aided care. Europe benefits from established movement disorder networks, EMA oversight, national reimbursement systems, health technology assessment, and active research in pharmacologic, surgical, digital, and rehabilitative Parkinson's disease care.

Asia-Pacific is gaining strategic importance as aging populations in Japan, China, South Korea, India, and Australia expand treatment demand and accelerate the need for neurologist access, essential medicines, and advanced therapies. Latin America, led by Brazil and Mexico, shows improving access through public health systems and expanding private care, although reimbursement and specialist availability remain uneven. The Middle East, especially GCC health systems, is investing in specialty hospitals, imported innovative medicines, and neurology centers, while Africa remains constrained by underdiagnosis, limited neurologist density, fragmented access to dopaminergic therapy, and affordability barriers.

Key Group Insights

The European Union and G7 anchor much of the global Parkinson's disease therapeutics innovation ecosystem through regulated clinical trials, academic neurology centers, pharmacovigilance systems, health technology assessment, and reimbursement for therapies with proven clinical value. NATO member countries also contribute through resilient medical supply chains, cross-border research collaboration, preparedness-focused health infrastructure, and standardized quality expectations across many advanced healthcare systems.

BRICS countries represent scale, manufacturing capacity, and expanding access to generics and affordable neurologic care, especially in China, India, and Brazil, while Russia emphasizes localized supply resilience. ASEAN markets are shaped by rising diagnosis, public hospital access, variable reimbursement, and growing demand for cost-effective Parkinson's disease medicines. GCC countries support premium specialty care, imported branded medicines, digital health adoption, and investment in neurology centers of excellence, strengthening access to advanced treatment pathways for eligible patients.

Key Country Insights

The United States leads commercial adoption through FDA approvals, specialist networks, Medicare coverage, movement disorder centers, and active clinical trials, while Canada emphasizes public reimbursement, guideline-based care, and equitable access across provinces. Mexico and Brazil show growing demand for affordable generics, expanded neurologic care, and improved continuity of treatment, with Brazil's public health system playing a central access role for essential medicines and specialist services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on health technology assessment, national reimbursement decisions, neurologist-led care pathways, and established use of levodopa and adjunctive therapies, while Russia focuses on localized supply resilience and access continuity. China is expanding access through hospital reform, reimbursement listing, domestic manufacturing, and broader neurology capacity; India is driven by high patient volume, generic availability, affordability considerations, and expanding specialist services in urban centers. Japan is shaped by super-aged demographics, high clinical awareness, and advanced management of motor complications, while Australia and South Korea combine strong reimbursement frameworks, modern neurology practice, and adoption of selected device-aided and digital care approaches.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that address motor fluctuations, dyskinesia, wearing-off, non-motor symptoms, adherence, safety, and caregiver burden. Strong differentiation requires real-world evidence, patient-reported outcomes, objective digital measures, and measurable functional benefit beyond traditional rating scales.

Organizations should pair pipeline investment with AI-enabled trial design, decentralized monitoring, biomarker strategies, and inclusive enrollment to reflect age, sex, ethnicity, disease stage, and comorbidity diversity. Market access teams need country-specific pricing, evidence, reimbursement, and affordability plans, while manufacturers should strengthen supply reliability for levodopa and other essential Parkinson's disease medicines to reduce treatment interruptions.

Research Methodology

This executive summary is based on triangulated secondary research from publicly available clinical, regulatory, epidemiologic, and health policy sources, including WHO disease burden data, national regulatory frameworks, treatment guidelines, peer-reviewed literature, clinical trial registries, pharmacovigilance references, and reimbursement information.

The analysis evaluates therapy classes, pipeline direction, regional access patterns, artificial intelligence adoption, digital health integration, technology use, and market access dynamics. Insights are validated through consistency checks across authoritative sources and interpreted using a structured healthcare market assessment framework focused on clinical relevance, regulatory context, access conditions, and evidence quality.

Conclusion

Parkinson's disease therapeutics will remain a high-priority healthcare category as prevalence rises with population aging and as patient needs expand beyond symptomatic motor control to include non-motor symptoms, long-term function, independence, and caregiver support. Current standards of care remain essential, but the competitive landscape is increasingly defined by delivery innovation, biomarkers, digital endpoints, and evidence-backed disease-modifying research.

Organizations that combine clinical differentiation, AI-enabled development, robust safety evidence, reliable supply, and region-specific access strategies will be best positioned to improve outcomes and create durable value in Parkinson's disease care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Parkinson's Disease Therapeutics Market, by Drug Class

  • 7.1. Anticholinergics
    • 7.1.1. Benztropine
    • 7.1.2. Trihexyphenidyl
  • 7.2. COMT Inhibitors
    • 7.2.1. Entacapone
    • 7.2.2. Tolcapone
  • 7.3. Dopamine Agonists
  • 7.4. Levodopa
  • 7.5. MAO-B Inhibitors

8. Parkinson's Disease Therapeutics Market, by Therapy Type

  • 8.1. Medications
  • 8.2. Non-Pharmacological Therapies
    • 8.2.1. Deep Brain Stimulation
    • 8.2.2. Physiotherapy
    • 8.2.3. Speech & Language Therapy

9. Parkinson's Disease Therapeutics Market, by Route Of Administration

  • 9.1. Infusion
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Transdermal

10. Parkinson's Disease Therapeutics Market, by Targeted Area

  • 10.1. Atypical Parkinsonian
  • 10.2. Drug-Induced Parkinsonism
  • 10.3. Genetic Parkinson's
  • 10.4. Idiopathic Parkinson's
  • 10.5. Vascular Parkinsonism

11. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 11.1. Offline
    • 11.1.1. Hospital Pharmacy
    • 11.1.2. Retail Pharmacy
  • 11.2. Online

12. Parkinson's Disease Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Parkinson's Disease Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Parkinson's Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Parkinson's Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Acadia Pharmaceuticals Inc.
  • 17.3. Novartis AG
  • 17.4. UCB S.A.
  • 17.5. Amneal Pharmaceuticals LLC
  • 17.6. Otsuka Pharmaceutical Co., Ltd.
  • 17.7. Sumitomo Pharma Co., Ltd.
  • 17.8. Orion Corporation
  • 17.9. Teva Pharmaceutical Industries Limited
  • 17.10. H. Lundbeck A/S
  • 17.11. Eisai Co., Ltd.
  • 17.12. Amyl Therapeutics SRL
  • 17.13. Apotex Inc.
  • 17.14. Aspen Neuroscience, Inc.
  • 17.15. Bayer AG
  • 17.16. Biogen Inc.
  • 17.17. BlueRock Therapeutics LP by Bayer AG
  • 17.18. Brainstorm Cell Therapeutics Ltd.
  • 17.19. Bristol-Myers Squibb Company
  • 17.20. Cerevance, LLC
  • 17.21. Cipla Limited
  • 17.22. Denali Therapeutics Inc.
  • 17.23. Eli Lilly and Company
  • 17.24. F. Hoffmann-La Roche Ltd.
  • 17.25. GlaxoSmithKline plc
  • 17.26. Lupin Limited
  • 17.27. Merck & Co., Inc.
  • 17.28. Muna Therapeutics ApS
  • 17.29. Pfizer Inc.
  • 17.30. Torrent Pharmaceuticals Ltd.
  • 17.31. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENZTROPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENZTROPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENZTROPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRIHEXYPHENIDYL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRIHEXYPHENIDYL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRIHEXYPHENIDYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTACAPONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENTACAPONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTACAPONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TOLCAPONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TOLCAPONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TOLCAPONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DOPAMINE AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DOPAMINE AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOPAMINE AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LEVODOPA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LEVODOPA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LEVODOPA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAO-B INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAO-B INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAO-B INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SPEECH & LANGUAGE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SPEECH & LANGUAGE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SPEECH & LANGUAGE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ATYPICAL PARKINSONIAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATYPICAL PARKINSONIAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ATYPICAL PARKINSONIAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG-INDUCED PARKINSONISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG-INDUCED PARKINSONISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG-INDUCED PARKINSONISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENETIC PARKINSON'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENETIC PARKINSON'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENETIC PARKINSON'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IDIOPATHIC PARKINSON'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IDIOPATHIC PARKINSON'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IDIOPATHIC PARKINSON'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR PARKINSONISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR PARKINSONISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR PARKINSONISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 216. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE,